ZIVO Bioscience: Algal Innovation Meets Funding Headwinds (ZIVO) - ZIVO Stock Research Report

## Executive Summary / Key Takeaways * ZIVO Bioscience is an R&D company leveraging proprietary algal technology to develop bioactive compounds for high-value applications in animal and human health, positioning itself in markets seeking natural, innovative solutions. * The company's technology shows potential in areas like poultry immune enhancement and avian influenza mitigation, attracting collaboration with a leading global animal health company, suggesting potential validation of its scientific approach. * Financially, ZIVO remains in a pre-revenue, high-cash-burn phase, reporting a $4.21 million net loss in Q1 2025, significantly higher than the prior year, driven primarily by non-cash expenses related to extinguishing past financing obligations. * Liquidity is a critical concern, with only $517,189 in cash as of March 31, 2025, and management noting substantial doubt about the company's ability to continue as a going concern without raising significant additional capital, estimated at $5 million over the next 12 months for basic operations alone. * While ZIVO's technology offers a potential competitive moat against larger, established players like Corbion (TICKER:CORB), DSM-Firmenich (TICKER:DSFIR), ADM (TICKER:ADM), and Zoetis (TICKER:ZTS), its early stage, lack of scale, and financial vulnerabilities pose significant risks to commercialization and market penetration. ## Algal Ambition in a Competitive Arena ZIVO Bioscience, Inc. is an R&D enterprise focused on unlocking the potential of proprietary algal cultures. Operating across the biotech and agtech sectors, the company aims to develop and commercialize natural bioactive ingredients for applications spanning animal health, human nutrition, and medicinal uses. This focus places ZIVO within a dynamic industry landscape driven by increasing demand for natural, sustainable, and scientifically validated health and wellness solutions. The company's journey, rooted in its history as Health Enhancement Products, Inc. and its transformation to ZIVO Bioscience in 2014, has been characterized by a persistent commitment to research and development, funded primarily through external capital. The competitive environment ZIVO faces is multifaceted. In the broader market for bioactive ingredients and animal/human health products, it contends with large, diversified players like Archer Daniels Midland Company (ADM) and DSM-Firmenich AG (DSFIR), which possess vast resources, established distribution networks, and economies of scale. More direct competition comes from companies specializing in fermentation and algal-based ingredients, such as Corbion N.V. (CORB). In specific animal health markets, like poultry health, ZIVO's potential products would compete with offerings from dominant players like Zoetis Inc. (TICKER:ZTS). These established competitors boast significant revenue streams, strong profitability margins (e.g., Zoetis with 71% gross margin and 37% operating margin in 2024), and robust cash flow generation, starkly contrasting with ZIVO's current financial profile.

Loading interactive chart...

## The Technological Edge: Cultivating a Moat At the heart of ZIVO's strategy is its intellectual property portfolio, encompassing proprietary algal and bacterial strains, bioactive molecules, and specialized production and cultivation techniques. This technology is the company's primary potential competitive advantage. ZIVO is developing specific compounds derived from its algae, targeting conditions such as poultry coccidiosis, bovine mastitis, human cholesterol, canine osteoarthritis, and avian influenza. The company's research suggests tangible benefits from its technology. For instance, studies indicate that active materials derived from ZIVO's algal culture showed positive effects in chickens challenged with avian influenza. Further collaborative studies with the University of Delaware have aimed to identify optimal formulations for mitigating Low Pathogenicity Avian Influenza (LPAI) virus, with recent results identifying a promising candidate for further testing. In animal health, ZIVO's algal-based products are posited to offer potential advantages, such as improved digestive efficiency for poultry or enhanced immune responses, potentially providing a differentiated offering compared to the antibiotic- or ionophore-based products that have dominated the coccidiosis market for decades. While specific, comprehensive quantitative performance metrics across all target applications are not publicly detailed, the strategic intent is clear: leverage proprietary biology to create high-efficacy, natural alternatives. This technological differentiation, if successfully translated into commercial products, could provide ZIVO with a competitive moat, potentially enabling higher pricing or faster market adoption in specific niches, countering the scale advantages of larger rivals. ## Strategic Pursuits and Operational Footprint ZIVO's strategy involves a dual focus: advancing its biotech candidates through research and seeking strategic partners for late-stage development and commercialization, and commercializing its algal biomass, branded ZivolifeTM, in the agtech sector. The selection of poultry coccidiosis as a lead biotech indication is strategic, aiming for rapid revenue generation due to the large global market and shorter clinical trial cycles in chickens. In agtech, the company is working towards commercial-scale production of its algal biomass in Peru using a proprietary pond design. The biomass, having received updated self-affirmed GRAS status for human consumption in early 2023, is being marketed as a functional food ingredient through an exclusive distributor, ZWorldwide, Inc., initially targeting the North American green powder market. Operational developments include the recent establishment of new leased facilities: a laboratory and office in Fort Myers, Florida, and a new headquarters office in Troy, Michigan, both commencing in January 2025. A notable strategic move in early 2025 involved entering into Exchange Agreements with holders of prior Participation Agreements, extinguishing rights to future revenue share or buy-out payments in exchange for common stock. This action, while resulting in significant non-cash R&D expense in Q1 2025, simplifies the company's capital structure and eliminates a potential future revenue-sharing obligation. ## Financial Realities and Liquidity Challenges ZIVO's financial performance reflects its early-stage, R&D-intensive nature. For the three months ended March 31, 2025, the company reported no commercial revenue, a decrease from $35,720 in the same period of 2024, attributed to a lack of product orders from its distributor. Costs of goods sold also decreased to $0, aligning with the absence of shipments. Operating expenses saw a substantial increase. Research and development expenses surged to $2.77 million in Q1 2025, up from $312,767 in Q1 2024. The vast majority of this increase, approximately $2.50 million, was a non-cash expense related to the extinguishment of Participation Agreements through the issuance of common stock. General and administrative expenses also rose to $1.44 million from $975,574, primarily due to higher professional fees, including legal, accounting, and board-related costs. These factors contributed to a significantly wider net loss of $4.21 million for the quarter, compared to a $1.28 million net loss in the prior year period.

Loading interactive chart...

Liquidity remains a critical challenge. As of March 31, 2025, ZIVO held cash of $517,189. The company has a history of net losses and negative operating cash flow, with an accumulated deficit reaching $141.18 million. Cash used in operating activities was $1.40 million in Q1 2025, an improvement from $1.70 million used in Q1 2024, primarily due to favorable changes in working capital. Financing activities provided $404,985 in Q1 2025, a significant decrease from $1.60 million in Q1 2024, as the company did not raise funds through common stock sales in the recent quarter, unlike the $1.10 million raised in the prior year period. Management has explicitly noted substantial doubt about the company's ability to continue as a going concern, stating that existing cash is insufficient to fund operations for the next twelve months. The company estimates needing approximately $5.00 million over the next 12 months just for basic operations, excluding R&D initiatives, highlighting a near-term and significant funding requirement.

Loading interactive chart...

## Competitive Pressures and Outlook ZIVO's competitive positioning is defined by its innovative technology set against the backdrop of well-capitalized, established players. While its proprietary algal strains and bioactive compounds offer potential advantages in efficacy or natural sourcing compared to synthetic alternatives or less specialized natural ingredients, ZIVO lacks the scale, manufacturing capacity, and extensive distribution networks of competitors like ADM, DSM-Firmenich, Corbion, or Zoetis. These larger companies can leverage economies of scale for potentially lower production costs and have existing relationships with major customers in the animal health and food ingredient markets. ZIVO's pre-revenue status and high R&D costs also mean it operates at significantly negative margins, whereas competitors enjoy substantial gross and operating profitability. The outlook for ZIVO is heavily contingent on its ability to secure additional funding. Management expects continued operating losses and negative cash flows until significant revenue is generated, and R&D costs are projected to grow, subject to funding availability. The need to raise capital is paramount, and there is no guarantee it can be obtained on favorable terms or at all. Failure to do so could necessitate curtailing operations, including critical R&D activities, or potentially ceasing operations entirely. Key risks include the inherent uncertainties of product development, regulatory approvals, the timing and success of clinical trials, the ability to scale production in Peru, dependence on the exclusive distributor for ZivolifeTM sales, and the ongoing remediation of identified material weaknesses in internal control over financial reporting. These control deficiencies, spanning areas from the control environment to specific accounting for complex transactions, add operational risk that needs to be effectively addressed. ## Conclusion ZIVO Bioscience presents a compelling narrative centered on the potential of its proprietary algal technology to address significant needs in the animal and human health markets. The company's R&D efforts and recent collaborations suggest a foundation of scientific promise and strategic intent to carve out a niche with differentiated, natural bioactive compounds. However, this potential is currently overshadowed by substantial financial and operational challenges. The company's pre-revenue state, high cash burn, limited liquidity, and explicit going concern warning underscore the critical need for significant external funding in the near term. For investors, ZIVO represents a high-risk, potentially high-reward opportunity. The investment thesis hinges on the successful development and commercialization of its product candidates, the ability to scale production, and the capacity to secure the necessary capital to bridge the gap to profitability. While the technological edge offers a potential competitive advantage, overcoming the scale and market dominance of established players requires successful execution on both the scientific and commercial fronts, all while navigating significant financial constraints and operational risks, including the ongoing efforts to strengthen internal controls. The path forward for ZIVO is one that demands close monitoring of funding progress, R&D milestones, and the effectiveness of its commercialization strategy.